Telomir Pharmaceuticals (NASDAQ:TELO) Announces Quarterly Earnings Results, Misses Expectations By $0.72 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) issued its quarterly earnings results on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.72), Zacks reports.

Telomir Pharmaceuticals Stock Performance

TELO opened at $1.05 on Friday. The stock has a market cap of $72.22 million, a price-to-earnings ratio of -3.62 and a beta of -0.24. The stock’s 50 day moving average price is $1.22 and its 200-day moving average price is $1.25. Telomir Pharmaceuticals has a one year low of $0.89 and a one year high of $2.09.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Qube Research & Technologies Ltd bought a new position in Telomir Pharmaceuticals in the 2nd quarter valued at $33,000. XTX Topco Ltd bought a new stake in shares of Telomir Pharmaceuticals during the fourth quarter worth $53,000. Bank of America Corp DE boosted its stake in shares of Telomir Pharmaceuticals by 283.9% during the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after purchasing an additional 10,880 shares during the period. Jane Street Group LLC purchased a new stake in shares of Telomir Pharmaceuticals during the second quarter valued at $62,000. Finally, Marshall Wace LLP bought a new position in shares of Telomir Pharmaceuticals in the second quarter worth about $95,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.